Takeda Pharmaceutical/$TAK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Primary listing
NYSE
Employees
47,455
Headquarters
Tokyo, Japan
Website
TAK Metrics
BasicAdvanced
$44B
25.24
$0.56
0.27
$0.54
3.93%
Price and volume
Market cap
$44B
Beta
0.27
52-week high
$15.69
52-week low
$12.80
Average daily volume
2.6M
Dividend rate
$0.54
Financial strength
Current ratio
1.158
Quick ratio
0.475
Long term debt to equity
68.014
Total debt to equity
73.419
Dividend payout ratio (TTM)
226.17%
Interest coverage (TTM)
4.20%
Profitability
EBITDA (TTM)
7,960.168
Gross margin (TTM)
64.98%
Net profit margin (TTM)
3.06%
Operating margin (TTM)
12.48%
Effective tax rate (TTM)
27.49%
Revenue per employee (TTM)
$616,490
Management effectiveness
Return on assets (TTM)
2.31%
Return on equity (TTM)
1.87%
Valuation
Price to earnings (TTM)
25.241
Price to revenue (TTM)
0.758
Price to book
0.98
Price to tangible book (TTM)
-3.61
Price to free cash flow (TTM)
4.157
Free cash flow yield (TTM)
24.05%
Free cash flow per share (TTM)
3.382
Dividend yield (TTM)
3.86%
Forward dividend yield
3.93%
Growth
Revenue change (TTM)
1.52%
Earnings per share change (TTM)
-9.74%
3-year revenue growth (CAGR)
7.64%
10-year revenue growth (CAGR)
9.47%
3-year earnings per share growth (CAGR)
-12.09%
10-year earnings per share growth (CAGR)
-8.02%
3-year dividend per share growth (CAGR)
2.88%
10-year dividend per share growth (CAGR)
0.86%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
Bulls say / Bears say
Core revenue rose 7.4% at actual exchange rates and core operating profit increased 4.9% at constant exchange rates in FY2024, driven by strong performance in Growth & Launch Products (Takeda May 8, 2025 Press Release)
Takeda’s solid cash flow allowed for a proposed dividend increase from ¥196 to ¥200 per share for FY2025, demonstrating financial strength and ongoing commitment to shareholder returns (Takeda May 8, 2025 Press Release)
Positive Phase 3 results from two key studies of Oveporexton in Narcolepsy Type 1 indicate the strength of Takeda’s late-stage pipeline and long-term growth prospects (Takeda July 30, 2025 Press Release)
Generic competition for VYVANSE caused a 3.7% revenue decrease at constant exchange rates and an 11.9% drop in core operating profit in Q1 FY2025, highlighting ongoing margin pressures (Takeda July 30, 2025 Press Release)
Takeda expects to incur a ¥58.0 billion impairment charge in Q2 FY2025 related to its gamma delta T-cell therapy platform, highlighting costly R&D setbacks in cell therapy before exiting the segment (Reuters)
FY2025 management guidance points to core revenue and operating profit remaining flat overall, as spending on R&D and product launches increases, signaling little near-term growth in earnings (Takeda May 8, 2025 Press Release)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
TAK Financial Performance
Revenues and expenses
TAK News
AllArticlesVideos
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
WSJ2 days ago
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
Reuters2 days ago
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Business Wire2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $44B as of October 24, 2025.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 25.24 as of October 24, 2025.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of October 24, 2025, the dividend rate is $0.54312 and the yield is 3.93%. Takeda Pharmaceutical has a payout ratio of 226.17% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.